Dr Ferras Alwan is a Consultant Haematologist specialising in bleeding disorders and thrombosis. His NHS practice is based at Imperial College NHS Trust where, in addition to being the Head of Service for Haemostasis and Thrombosis, he is the centre director of the Imperial Haemophilia Comprehensive Care Centre.

Areas of expertise

• Deep vein thrombosis and pulmonary embolism
• Thrombophilias
• Haemophilia and rare bleeding disorders
• Thrombotic Thrombocytopenic Purpura 
• Low platelets

Current and recent appointments

• Consultant Haematologist - Imperial College Healthcare Trust
• Centre Director - Imperial Haemophilia Comprehensive Care Centre

Publications, lectures and teachings

• Alwan F, Vendramin C, Liesner R, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura, Blood
• Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura, Blood
• Underwood M, Alwan F, et al. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura, J Thromb Haemost
• Alwan F, Vendramin C, Budde U, et al. Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura, eJHaem
• Alwan F, Mahdi D, Tayabali S et al. Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura, British Journal of Haematology
• Arulkumaran N, Thomas M, Brealey, D et al. Plasma exchange for COVID‐19 thrombo‐inflammatory disease, eJHaem
• Westwood J-P, Thomas M, Alwan F, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens, Blood Advances
• Vendramin C, McGuckin S, Alwan F, et al. A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy, Transfusion
• Alwan F, He A, Montoto S, et al. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy, AIDS